The global Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 61.6 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Human Immunoglobulin (pH4) for Intravenous Injection is derived from human plasma pooled from thousands of healthy plasma donors. It contains antibodies against various antigens thereby providing passive and immediate immunization against various infectious agents. With growing incidences of neurological, immunological and hematological disorders where immunoglobulin therapies play a vital role, the demand for Human Immunoglobulin (pH4) for Intravenous Injection is increasing rapidly. The products offer lifelong immunity against certain infections and help strengthen the immune system of immunodeficient patients.
Market key trends:
One of the key trends in the Human Immunoglobulin (pH4) for Intravenous Injection market is the rising preference for subcutaneous immunoglobulin therapy. Subcutaneous immunoglobulin infusion takes less time as compared to intravenous immunoglobulin therapy and has lesser side effects. It maintains stable and adequate antibody levels in the body for a longer duration between doses. Researchers are also working on developing newer formulations and delivery methods such as lyophilized powder for subcutaneous immunoglobulin to provide higher convenience and compliance for patients.
Porter’s Analysis
Threat of new entrants: The regulatory barriers and requirements for setting up facilities to produce human immunoglobulin (pH4) for intravenous injection and getting product approvals pose high entry barriers for new players.
Bargaining power of buyers: The buyers have moderate bargaining power as there are many established players offering the product. However, the buyers cannot switch easily to alternative products due to regulations.
Bargaining power of suppliers: The suppliers have moderate bargaining power as raw material suppliers are few for this niche market and they have established relationships with key players.
Threat of new substitutes: There are limited product substitutes for human immunoglobulin (pH4) for intravenous injection due to its unique therapeutic properties.
Competitive rivalry: The competition is high among the key established global players in the market.
Key Takeaways
The Global Human Immunoglobulin (Ph4) For Intravenous Injection Market Demand is expected to witness high growth, exhibiting 12% CAGR over the forecast period 2023-2030, due to increasing prevalence of immunodeficiency and autoimmune diseases.
Regional analysis: North America is expected to dominate the global human immunoglobulin (pH4) for intravenous injection market over the forecast period owing to rising ageing population, increasing healthcare spending, and strong presence of key market players in the region. However, Asia Pacific is anticipated to exhibit the fastest growth during the forecast period due to growing patient pool, rising awareness about immunoglobulin therapy and increasing healthcare expenditure in emerging economies of China and India.
Key players operating in the human immunoglobulin (pH4) for intravenous injection market include Takeda Pharmaceutical Company Limited, Baxter, CSL, Bayer AG, Grifols, S.A, Octapharma Brasil Ltda, Shanghai RAAS Blood Products Co Ltd, Hualan Biological Engineering, Inc, Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc), China Resources Boya Bio-pharmaceutical Group Co Ltd, ADMA Biologics, Inc, Sinopharm Group Co. Ltd. Takeda Pharmaceutical Company Limited is one of the leading players offering wide range of human immunoglobulin products.
The Human Immunoglobulin(ph4) for Intravenous Injection Market Research Report Forecast is a valuable source of insightful data for business strategists.
It provides the industry overview with recent trends, size, share, growth analysis, historical, futuristic data, revenue, demand and strategic development.The entire human immunoglobulin ph4 for intravenous injection market has been sub-categorized into product type and end-users.
The report provides an analysis of these subsets with respect to the geographical segmentation.
This research study will keep marketer informed and helps to identify the target demographics for a product or service.Request a FREE Sample Copy of Global Human Immunoglobulin(ph4) for Intravenous Injection Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/human-immunoglobulin-ph4-for-intravenous-injection-market/download-sampleBy Product Type1g/20ml25g/25ml5g/50ml5g/100ml10g/200mlBy End UsersHospitalClinicOthersBrowse Full Global Human Immunoglobulin(ph4) for Intravenous Injection Market Research Report With TOC At: https://www.valuemarketresearch.com/report/human-immunoglobulin-ph4-for-intravenous-injection-marketThe research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the human immunoglobulin ph4 for intravenous injection market include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB, NanyueBiopharming.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.This section covers regional segmentation which accentuates on current and future demand for human immunoglobulin ph4 for intravenous injection market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
The new research report titled "Intravenous Immunoglobulin Market, Global Industry Analysis, and Forecast to 2027" gives a detailed analysis and future forecasts of the market.
The report highlights the significant players, including market size, share, and demand, development.
This report further covers the latest trends, technological advancements, and growth opportunities.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the intravenous immunoglobulin market include LFB Biotechnologies, Biotest, Octapharma, Grifols, CSL Behring, China Biologics Products, KedrionBiopharma, BDI Pharma, Shire, CSL Behring.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Intravenous Immunoglobulin Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/intravenous-immunoglobulin-market/download-sampleMarket DynamicsThe global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects.
As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis.
